A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with hemophilia (A or B) and inhibitors

Trial Profile

A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with hemophilia (A or B) and inhibitors

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs CSL 689 (Primary) ; Eptacog alfa
  • Indications Haemophilia A; Haemophilia B
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors CSL Behring
  • Most Recent Events

    • 05 Sep 2017 Planned End Date changed from 1 Jun 2019 to 8 Nov 2019.
    • 05 Sep 2017 Planned primary completion date changed from 1 May 2019 to 25 Oct 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top